Newsfeeds - Spark Newswire

3 minute read

Mid-Afternoon Market Update: Dow Rises 70 Points; IDEAYA Biosciences Shares Slide

Today, 1:23 PM

Toward the end of trading Wednesday, the Dow traded up 0.20% to 34,647.52 while the NASDAQ rose 0.01% to 14,664.04. The S&P also rose, gaining 0.33% to 4,358.01.

BLIN

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 1:23 PM

Gainers

ADXS

3 minute read

Mid-Day Market Update: Crude Oil Down 2.5%; Opiant Pharmaceuticals Shares Jump

By Lisa Levin

Today, 1:23 PM

Midway through trading Wednesday, the Dow traded down 0.23% to 34,499.42 while the NASDAQ fell 0.30% to 14,619.40. The S&P also fell, dropping 0.11% to 4,338.70.

BLIN

4 minute read

42 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 1:23 PM

Gainers Newegg Commerce, Inc. (NASDAQ: NEGG) jumped 79% to $48.70 after jumping around 42% on Tuesday.

AMST

10 minute read

Stocks That Hit 52-Week Highs On Wednesday

By Benzinga Insights

Today, 1:23 PM

Before 10 a.m. ET Wednesday, 138 stocks hit new 52-week highs.

1 minute read

12 Health Care Stocks Moving In Wednesday’s Pre-Market Session

By Benzinga Insights

Today, 1:23 PM

AKTX

1 minute read

Opiant Pharma Stock Surges On Positive Nasal Nalmefene Data In Opioid Overdose Study

By Vandana Singh

Today, 1:23 PM

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) announced top-line results from its confirmatory pharmacokinetic study for OPNT003, nasal nalmefene, for opioid overdose. The 68-subject…

OPNT

5 minute read

The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend

By Shanthi Rexaline

Today, 1:23 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6)

ABCL

2 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s After-Market Session

By Benzinga Insights

Today, 1:23 PM

Gainers

ADXS

1 minute read

News

Looking Into Opiant Pharmaceuticals’s Return On Capital Employed

By Benzinga Insights

Today, 1:23 PM

In Q1, Opiant Pharmaceuticals (NASDAQ:OPNT) posted sales of $6.39 million. Earnings were up 152.19%, but Opiant Pharmaceuticals still reported an overall loss of $2.32 million. In Q4, Opiant Pharmaceuticals brought in $9.92 million in sales but lost $920.52 thousand in earnings.

OPNT